spc-839 and Leukemia--Myeloid--Acute

spc-839 has been researched along with Leukemia--Myeloid--Acute* in 4 studies

Reviews

1 review(s) available for spc-839 and Leukemia--Myeloid--Acute

ArticleYear
Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade.
    European journal of medicinal chemistry, 2019, Sep-15, Volume: 178

    Acute myeloid leukemia (AML) is a malignant disease characterized by abnormal growth and differentiation of hematopoietic stem cells. Although the pathogenesis has not been fully elucidated, many specific gene mutations have been found in AML. Fms-like tyrosine kinase 3 (FLT3) is recognized as a drug target for the treatment of AML, and the activation mutations of FLT3 were found in about 30% of AML patients. Targeted inhibition of FLT3 receptor tyrosine kinase has shown promising results in the treatment of FLT3 mutation AML. Unfortunately, the therapeutic effects of FLT3 tyrosine kinase inhibitors used as AML monotherapy are usually accompanied by the high risk of resistance development within a few months after treatment. FLT3 dual inhibitors were generated with the co-inhibition of FLT3 and another target, such as CDK4, JAK2, MEK, Mer, Pim, etc., to solve the problems mentioned above. As a result, the therapeutic effect of the drug is significantly improved, while the toxic and side effects are reduced. Besides, the life quality of AML patients with FLT3 mutation has been effectively improved. In this paper, we reviewed the studies of dual FLT3 inhibitors that have been discovered in recent years for the treatment of AML.

    Topics: Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Molecular Structure; Protein Kinase Inhibitors; Structure-Activity Relationship

2019

Other Studies

3 other study(ies) available for spc-839 and Leukemia--Myeloid--Acute

ArticleYear
Sensitivity and gene expression profile of fresh human acute myeloid leukemia cells exposed ex vivo to AS602868.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:1

    The need for new treatment options for acute myeloid leukemia (AML) is increasing. AS602868 is a novel investigational drug with reported activity on AML cells.. We studied gene expression profiles in AML blasts exposed to AS602868 in order to better understand its mechanism of action. We analyzed the in vitro cytotoxicity of AS602868 alone or in combination with daunorubicin, etoposide or cytarabine. To document AS602868-induced IKK2 inhibition in fresh AML cells, a flow cytometry analysis of IκB was performed. Finally, the effect of AS602868 on gene expression in fresh AML cells was analyzed.. The results show that AML cells are globally as sensitive to AS602868 as they are to cytarabine, with large interindividual variations. Combinations with conventional antileukemic agents showed enhanced cytotoxic activity in subsets of patients. IKK2 appeared to be effectively inhibited by 100 μM AS602868 in fresh leukemic cells. Gene expression profiling and gene ontology analyses identified several groups of genes induced/inhibited by exposure to AS602868 and/or exhibiting a correlation with sensitivity to this agent in vitro. Of note, the expression of several genes related to immune function was found to be significantly altered after exposure to AS602868.. These data suggest that AS602868 is cytotoxic against fresh human AML blasts and provide insights regarding the mechanisms of cytotoxicity.

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Etoposide; Gene Expression Profiling; Humans; I-kappa B Proteins; Leukemia, Myeloid, Acute; Lymphocytes; Oligonucleotide Array Sequence Analysis; Pyrimidines

2011
Preclinical targeting of NF-kappaB and FLT3 pathways in AML cells.
    Leukemia, 2008, Volume: 22, Issue:7

    Topics: Animals; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred C57BL; Neoplastic Stem Cells; NF-kappa B; Pyrimidines

2008
AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells.
    Leukemia, 2007, Volume: 21, Issue:5

    Acute myeloid leukemia (AML) cells carry molecular defects that promote their leukemic proliferation, resistance to apoptosis and defect in differentiation. Pharmacological targeting of the nuclear factor kappaB (NF-kappaB) pathway has been shown to promote apoptosis of primary AML cells and to sensitize blasts to neoplastic drugs (Frelin, Blood 2005, 105, 804). The Fms-like tyrosine kinase 3 (FLT3), which sustains proliferation of normal hematopoietic progenitors is frequently overexpressed or mutated in AML patients. Using Ba/F3 murine pre-B cells transfected with various mutants of FLT3 (ITD, D835V, D835Y) and the MV4-11 human AML line, we show that normal or oncogenic stimulation of FLT3 led to activation of NF-kappaB. Pharmacological inhibition of either FLT3 with AG1296 or NF-kappaB with the small molecule inhibitor of IkappaB kinase-2 AS602868 reduced viability and triggered cell death. Moreover, AS602868 was also found to interfere directly with FLT3 kinase activation. AS602868 thus appears to target two different kinases that play a crucial role in the pathogenesis of AML, making it particularly attractive as a new therapeutical approach for AML.

    Topics: Animals; Annexin A5; bcl-X Protein; Caspase 3; Cell Line; Cell Proliferation; Child; fms-Like Tyrosine Kinase 3; Humans; I-kappa B Kinase; Leukemia, Myeloid, Acute; Male; Mice; NF-kappa B; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Pyrimidines

2007